BioCis Pharma has initiated a first-in-man study with ProtoCure(TM) emulsion cream
2008-03-04
BioCis Pharma has initiated a first-in-man study with ProtoCure(TM) emulsion creamBioCis Pharma Ltd., a privately-held drug development company with its headquarters inTurku, Finland, announced today that it has initiated a double-blind, placebo-controlledsingle centre phase I study in Finland to investigate the pharmacokinetics, safety andtolerability of its topical ProtoCure(TM) emulsion cream in healthy volunteers.
The clinical trialis a two-period study, where the efficacy of the ProtoCure(TM) emulsion cream is evaluatedin a skin irritation reaction during the second period."We are excited about this first-in-man study. The first subjects were dosed last week, andthe investigational drug has been well tolerated. We expect the study to be completed bythe end of March, and the results should be available by summer. The next clinical trialswith the ProtoCure(TM) cream have been scheduled for the second half of this year" said Dr.Lasse Leino, CEO of BioCis Pharma Ltd.BioCis Pharma is developing the ProtoCure(TM) emulsion cream for the treatment of skininflammation, such as dermatitis and psoriasis. It is a first-in-class pharmaceutical,containing a small-molecule active substance that produces a local anti-inflammatoryeffect by breaking the intracellular pH balance of inflammatory cells in a controlled manner.This new mode of action, named the Protodynamic Therapy Concept, has beendemonstrated to be highly efficient in preclinical models of local inflammation. TheProtoCure(TM) emulsion cream is the company's lead product and also is in a phase I trialfor local treatment of actinic keratosis.BioCis Pharma Ltd is an innovative drug development company with a business idea todevelop drug therapies based on a novel, patented therapeutic principle. BioCis Pharmais targeting unmet medical needs in substantial therapeutic markets includinginflammation, allergy, and cancer. The company's main investors are KarolinskaDevelopment AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Ltd.
Contacts:Dr. Lasse Leino, CEO, BioCis Pharma Ltd.,
mobile phone +358 40 849 4694, lasse.leino[at]biocis.